LEAPS, ChiCTR2000037821: Combining pharmacokinetics and comprehensive evaluation system to guide the prophylaxis of Chinese pediatric hemophilia A patients with Kovaltry |
|
|
| Not yet recruiting | 4 | 60 | | adjust dosing regimens under the | Beijing Children’s Hospital, Capital Medical University; Beijing Children's Hospital, Bayer company | Hemophilia A | | | | |
2021-003537-11: A Post Approval Commitment study to evaluate the efficacy, safety, and pharmacokinetics of KOVALTRY in Chinese children, adolescents/adults with severe hemophilia A. |
|
|
| Not yet recruiting | 4 | 48 | RoW | Kovaltry, BAY 81-8973, Powder for solution for injection/infusion, Kovaltry | Bayer Healthcare Company Limited, Bayer Healthcare Company Limited | KOVALTRY, indicated for use in adults and children with hemophilia A (congenital Factor VIIIdeficiency) for:- Routine prophylaxis to reduce the frequency of bleeding episodes- On-demand treatment and control of bleeding episodes- Perioperative management of bleeding, Treatment of hemophilia A patients (lacking of native FVIII), Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
NCT04565236: A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A |
|
|
| Completed | 4 | 45 | RoW | Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1, Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2, Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 3 | Bayer | Hemophilia A | 03/24 | 03/24 | | |
